OncoCyte Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte or view top-rated stocks.

Wall Street analysts have given OncoCyte a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OncoCyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

OncoCyte is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for OncoCyte.

OncoCyte Co. (NYSEAMERICAN:OCX) released its quarterly earnings results on Monday, August, 9th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.02. The biotechnology company had revenue of $2.03 million for the quarter, compared to analyst estimates of $1.65 million. OncoCyte had a negative net margin of 652.99% and a negative trailing twelve-month return on equity of 36.24%.
View OncoCyte's earnings history.

OncoCyte's stock was trading at $2.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OCX shares have increased by 87.9% and is now trading at $4.02.
View which stocks have been most impacted by COVID-19.

5 brokers have issued 12 month price objectives for OncoCyte's shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate OncoCyte's stock price to reach $6.60 in the next year. This suggests a possible upside of 64.2% from the stock's current price.
View analysts' price targets for OncoCyte or view top-rated stocks among Wall Street analysts.

Some companies that are related to OncoCyte include Meridian Bioscience (VIVO), Alpha Teknova (TKNO), Aspira Women's Health (AWH), Lucira Health (LHDX), Quotient (QTNT), MyMD Pharmaceuticals (MYMD), Nymox Pharmaceutical (NYMX), VolitionRx (VNRX), Achieve Life Sciences (ACHV), ImmuCell (ICCC), Biomerica (BMRA), Trinity Biotech (TRIB), Navidea Biopharmaceuticals (NAVB), ARCA biopharma (ABIO) and Global WholeHealth Partners (GWHP).
View all of OCX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include Alibaba Group (BABA), Brooklyn ImmunoTherapeutics (BTX), Fulcrum Therapeutics (FULC), Alnylam Pharmaceuticals (ALNY), VIVUS (VVUS), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX) and Aldeyra Therapeutics (ALDX).

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

OncoCyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.17%), Vanguard Group Inc. (4.27%), Nuveen Asset Management LLC (1.60%), Schonfeld Strategic Advisors LLC (1.52%), Defender Capital LLC. (1.47%) and State Street Corp (1.38%). Company insiders that own OncoCyte stock include Albert P Parker, Alfred D Kingsley, Broadwood Partners, LP, Mitchell S Levine and Ronald Asbury Andrews.
View institutional ownership trends for OncoCyte.

OCX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Schonfeld Strategic Advisors LLC, Marshall Wace LLP, Marshall Wace LLP, Bridgeway Capital Management LLC, AWM Investment Company Inc., JPMorgan Chase & Co., and Millennium Management LLC.
View insider buying and selling activity for OncoCyte or view top insider-selling stocks.

OCX stock was purchased by a variety of institutional investors in the last quarter, including Defender Capital LLC., Nuveen Asset Management LLC, Maven Securities LTD, Goldman Sachs Group Inc., Cinctive Capital Management LP, State Street Corp, Vanguard Group Inc., and Dimensional Fund Advisors LP. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Broadwood Partners, LP, Mitchell S Levine, and Ronald Asbury Andrews.
View insider buying and selling activity for OncoCyte or or view top insider-buying stocks.

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OCX stock can currently be purchased for approximately $4.02.

OncoCyte has a market capitalization of $368.16 million and generates $1.22 million in revenue each year. The biotechnology company earns $-29,930,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

OncoCyte employs 51 workers across the globe.

The official website for OncoCyte is www.oncocyte.com.

OncoCyte is headquartered at 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States.

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (949) 409-7600 or via email at [email protected].